Navigation Links
Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
Date:4/14/2008

- Faster delivery, efficient supply chain, and reduced cost for

pharmaceutical manufacturers

NEW YORK, April 14 /PRNewswire/ -- Sumitomo Corporation of America (SCOA) has reached an agreement with Chiral Quest, Inc., a manufacturer and developer of chiral products using proprietary chiral technologies, for the distribution and sale of chiral products to the pharmaceutical industry.

Effective immediately, Sumitomo will be the exclusive sales agent for Chiral Quest in Japan and selected worldwide accounts.

More than 40 percent of the ethical drugs manufactured today utilize chiral intermediate technology. Chiral chemocatalysts play a key role in the manufacture of medicines, fine chemicals, agricultural chemicals, and flavors and fragrances.

"Chiral Quest is now in an expansion phase, and Sumitomo's international network of marketing and distribution facilities will enable us to provide our specialty chiral molecules quickly to pharmaceutical manufacturers globally at competitive prices," said Dr. Joseph Marasco, CEO of Chiral Quest. "This is a venture that will be welcomed by the chiral molecule marketplace, and will allow us to efficiently serve our growing client base."

Chiral Quest has wholly owned patents on a range of innovative chemical catalysts and processes used in the synthesis of chiral molecules. The company's primary laboratory and manufacturing facilities in New Jersey and China will now be supported by Sumitomo's extensive marketing capability and distribution network. Additional information on Chiral Quest is available at their website http://www.chiralquest.com/.

"Sumitomo has been a major supplier to the global pharmaceutical industry for over the past four decades," noted Yasunori Ishibashi, senior director of the SCOA Medical Sciences Group. "This collaboration makes it possible for Sumitomo to play a significant role in the innovative and growing field of chiral technology."

Sumitomo's established supply chain provides chemicals for a range of manufacturing processes. The company's chemical experts help specific clients in the field select and implement the most efficient synthesis process for producing specific molecules.

The catalytic asymmetric hydrogenation process was discovered in 1987 by Dr. Ryoji Nyori. Over the past two decades, Nyori chiral technology has evolved rapidly and become widely applied in chemocatalysis. It has been especially valuable in the manufacture of chiral pharmaceutical products and fine chemicals. In 2001 Dr. Nyori shared the Nobel Prize in Chemistry with William S. Knowles for their work in the study of chirally catalyzed hydrogenation.

Sumitomo's global network includes 148 offices in 67 countries. Sumitomo also provides unique expertise in the import and export business.

Through its global network for sales and distribution, Sumitomo has become a major resource for pharmaceutical companies. Sumitomo provides raw materials, production facilities, R&D facilities and various technical process support to major manufacturers in the pharmaceutical industry.

About Sumitomo Corporation of America

Sumitomo Corporation of America (SCOA), is a fully integrated trading and investment enterprise with offices in 11 major U.S. cities. SCOA is the largest wholly owned subsidiary of Sumitomo Corporation (SC), an integrated global trading firm with diversified investments and businesses. Established in 1952, and headquartered in New York, SCOA is involved in a wide range of industries, including working on a global scale with SC and subsidiaries to expand on emerging opportunities in the pharmaceutical industry. http://www.sumitomocorp.com


'/>"/>
SOURCE Sumitomo Corporation of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
2. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
3. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
4. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
5. Chem Rx Corporation Reports Full Year 2007 Financial Results
6. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
7. Genaera Corporation Announces 2007 Financial Results
8. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... type 2 diabetes, announced that it has obtained ... (AAV) vector developed in the laboratory of Professor ... University. The company plans to use this vector ... pipeline. "Early research has shown ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
Breaking Biology Technology:
(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
Breaking Biology News(10 mins):